Premium
Effects of FK506 on myasthenia gravis patients with high interleukin‐2 productivity in peripheral blood mononuclear cells
Author(s) -
Utsugisawa Kimiaki,
Nagane Yuriko,
Yonezawa Hisashi,
Obara Daiji,
Kondoh Ryushi,
Tohgi Hideo
Publication year - 2003
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.10285
Subject(s) - peripheral blood mononuclear cell , myasthenia gravis , medicine , endocrinology , acetylcholine receptor , peripheral , peripheral blood , interleukin 2 , interleukin , immunology , cytokine , receptor , chemistry , in vitro , biochemistry
We compared the early effects of FK506 on clinical severity, interleukin‐2 (IL‐2) production by phytohemagglutinin‐stimulated peripheral blood mononuclear cells (PBMs), and serum levels of acetylcholine receptor antibodies between myasthenia gravis (MG) patients with elevated (>1250 pg/ml, n = 9) or normal (<1250 pg/mL, n = 10) levels of PBM IL‐2 production. Reduction in clinical severity and PBM IL‐2 production were significantly greater in the patients with elevated IL‐2 production than those with normal PBM IL‐2 production in the first month of treatment. Muscle Nerve 27: 245–248, 2003